Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondyloarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR2302, a recombinant CD3xpMHC (HBV-S); GR2301, a recombinant anti-IL-15 monoclonal antibody; GR2304, a recombinant CD3xpMHC (PRAME); GR2502, a TCR-based antibody (TCRm); GR2603, a recombinant humanized trispecific antibody; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China. Address: Building 2, Chongqing, China, 401338